" class="no-js "lang="en-US"> COVID-19 Archives - Medtech Alert
Friday, March 01, 2024

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19

Senhwa Biosciences, a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and […]

ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment

Shionogi today announced that two late-breaking poster presentations featuring new results from the Phase 3 […]

PharmaJet Announces Clinical Results from Scancell’s COVID-19 DNA Vaccine Study Exclusively Administered with Needle-free Precision Delivery Systems

PharmaJet, a company engineering precision delivery systems that may overcome the challenges of nucleic acid […]

COVID-19 Rapid Antigen Self-Test, COVI-Go, receives FDA Emergency Use Authorization for Home Use

Mologic, the US subsidiary of Global Access Diagnostics (GADx), a leading developer of lateral flow […]

U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]

Antiparasitic Drug Could Prevent Coronavirus Lung Damage

A common antiparasitic drug could block lung damage in people with coronavirus, according to new […]

GSK to support manufacture of Novavax' COVID-19 vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the […]

Moderna 100 Millionth Dose Shipment of COVID-19 Vaccine to U.S.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

AZD1222 US Phase III Primary Analysis Confirms Vaccine Safety and Efficacy

76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more